Literature DB >> 2578431

Enhancement of immunity against RSV-induced sarcomas by generation of hapten-reactive helper T lymphocytes.

P M Comoglio, M Prat, S Bretti.   

Abstract

Previous work from this laboratory has shown that preimmunization of syngeneic hosts with Rous sarcoma virus (RSV)-transformed cells elicits a strong immune response against the growth of transplantable RSV sarcomas, mediated by T lymphocytes expressing the surface phenotype of helper cell precursors (Prat, Di Renzo & Comoglio, 1983). This paper shows that anti-tumour immunity may be elicited in tumour-bearing animals by triggering an experimentally pre-amplified T-helper cell population at the site of tumour growth. Mice were treated with cyclophosphamide (which inactivates suppressor T cells) followed by skin sensitization to trinitrochlorobenzene (TNCB) according to a protocol that has been shown to induce an appreciably amplified generation of trinitrophenyl (TNP)-reactive helper T cells (Fujiwara et al., 1984). Five weeks after TNCB painting, mice were transplanted s.c. with a lethal dose of RSV-induced syngeneic sarcoma cells; the injection at the tumour site of TNCB induced the regression of the tumour in mice in which the TNP-helper cell population has been amplified, but not in controls, including those injected with a non-related hapten or sensitized to TNCB without inactivation of suppressors.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2578431      PMCID: PMC1453510     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  33 in total

1.  Target antigens for antibodies and complement at the cell surface of RSV-transformed fibroblasts.

Authors:  M Prat; F Tato; G Tarone; P M Comoglio
Journal:  Immunology       Date:  1980-02       Impact factor: 7.397

2.  Interaction between cellular and viral genes in the expression of the RSV-induced transformation-specific cell-surface antigen VCSA.

Authors:  M Prat; F Tatò; G Tarone; P M Comoglio
Journal:  Int J Cancer       Date:  1980-03-15       Impact factor: 7.396

3.  The augmentation of in vitro and in vivo tumor-specific T cell-mediated immunity by amplifier T lymphocytes.

Authors:  H Fujiwara; T Hamaoka; G M Shearer; H Yamamoto; W D Terry
Journal:  J Immunol       Date:  1980-02       Impact factor: 5.422

4.  Immune response to the src gene product in mice bearing tumors induced by injection of avian sarcoma virus-transformed mouse cells.

Authors:  S J Parsons; S C Riley; E E Mullen; E J Brock; D C Benjamin; W M Kuehl; J T Parsons
Journal:  J Virol       Date:  1979-10       Impact factor: 5.103

5.  T cell-mediated immunity to oncornavirus-induced tumors. I. Ly phenotype of precursor and effector cytolytic T lymphocytes.

Authors:  J C Leclerc; H Cantor
Journal:  J Immunol       Date:  1980-02       Impact factor: 5.422

6.  Immunotherapy of a chemically-induced sarcoma in rats: characterization of the effector T cell subset and nature of suppression.

Authors:  E Fernandez-Cruz; S C Gilman; J D Feldman
Journal:  J Immunol       Date:  1982-03       Impact factor: 5.422

7.  Mouse fibroblasts transformed by Rous sarcoma virus express a virus-specific non-virion transplantation antigen.

Authors:  M Prat; G Tarone; P M Comoglio
Journal:  Int J Cancer       Date:  1981-06-15       Impact factor: 7.396

8.  Dissection of the antigenic determinants expressed on the cell surface of RSV-transformed fibroblasts by monoclonal antibodies.

Authors:  R Ferracini; M Prat; P M Comoglio
Journal:  Int J Cancer       Date:  1982-04-15       Impact factor: 7.396

9.  T cell-mediated immunity to oncornavirus-induced tumors. II. Ability of different T cell sets to prevent tumor growth in vivo.

Authors:  J C Leclerc; H Cantor
Journal:  J Immunol       Date:  1980-02       Impact factor: 5.422

10.  Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2- lymphocytes.

Authors:  P D Greenberg; M A Cheever; A Fefer
Journal:  J Exp Med       Date:  1981-09-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.